aTyr Pharma (NASDAQ: ATYR), a clinical stage biotech company, has announced its participation in three upcoming investor conferences in May-June 2025. CEO Sanjay S. Shukla will present at the RBC Capital Markets Global Healthcare Conference (May 21), Piper Sandler Virtual Lung Symposium (May 27), and Jefferies Global Healthcare Conference (June 5). The presentations at RBC and Jefferies will be available via webcast on the company's website for 90 days, with one-on-one investor meetings available at these events. aTyr focuses on developing first-in-class medicines from tRNA synthetase biology, with their lead candidate efzofitimod targeting interstitial lung disease treatment.
aTyr Pharma (NASDAQ: ATYR), una società biotecnologica in fase clinica, ha annunciato la sua partecipazione a tre conferenze per investitori previste tra maggio e giugno 2025. Il CEO Sanjay S. Shukla presenterà al RBC Capital Markets Global Healthcare Conference (21 maggio), al Piper Sandler Virtual Lung Symposium (27 maggio) e al Jefferies Global Healthcare Conference (5 giugno). Le presentazioni di RBC e Jefferies saranno disponibili in webcast sul sito web dell'azienda per 90 giorni, con incontri individuali con investitori disponibili durante questi eventi. aTyr si concentra sullo sviluppo di farmaci innovativi basati sulla biologia della tRNA sintetasi, con il candidato principale efzofitimod, mirato al trattamento delle malattie polmonari interstiziali.
aTyr Pharma (NASDAQ: ATYR), una empresa biotecnológica en fase clínica, ha anunciado su participación en tres próximas conferencias para inversores en mayo-junio de 2025. El CEO Sanjay S. Shukla presentará en la RBC Capital Markets Global Healthcare Conference (21 de mayo), el Piper Sandler Virtual Lung Symposium (27 de mayo) y la Jefferies Global Healthcare Conference (5 de junio). Las presentaciones en RBC y Jefferies estarán disponibles en webcast en la página web de la empresa durante 90 días, con reuniones individuales para inversores en estos eventos. aTyr se enfoca en desarrollar medicamentos innovadores basados en la biología de la tRNA sintetasa, con su principal candidato efzofitimod dirigido al tratamiento de enfermedades pulmonares intersticiales.
aTyr Pharma(NASDAQ: ATYR)는 임상 단계의 바이오테크 기업으로, 2025년 5월부터 6월 사이에 열리는 세 건의 투자자 컨퍼런스에 참가할 예정임을 발표했습니다. CEO Sanjay S. Shukla는 RBC Capital Markets Global Healthcare Conference(5월 21일), Piper Sandler Virtual Lung Symposium(5월 27일), 그리고 Jefferies Global Healthcare Conference(6월 5일)에서 발표할 예정입니다. RBC와 Jefferies에서의 발표는 회사 웹사이트를 통해 90일간 웹캐스트로 제공되며, 해당 행사에서는 1:1 투자자 미팅도 진행됩니다. aTyr는 tRNA 합성효소 생물학을 기반으로 한 혁신적인 의약품 개발에 주력하고 있으며, 주요 후보물질인 efzofitimod는 간질성 폐질환 치료를 목표로 하고 있습니다.
aTyr Pharma (NASDAQ : ATYR), une société biotechnologique en phase clinique, a annoncé sa participation à trois conférences pour investisseurs prévues entre mai et juin 2025. Le PDG Sanjay S. Shukla présentera lors de la RBC Capital Markets Global Healthcare Conference (21 mai), du Piper Sandler Virtual Lung Symposium (27 mai) et de la Jefferies Global Healthcare Conference (5 juin). Les présentations à RBC et Jefferies seront disponibles en webcast sur le site de la société pendant 90 jours, avec des rencontres individuelles avec les investisseurs lors de ces événements. aTyr se concentre sur le développement de médicaments innovants issus de la biologie de la tRNA synthétase, avec son principal candidat efzofitimod ciblant le traitement des maladies pulmonaires interstitielles.
aTyr Pharma (NASDAQ: ATYR), ein Biotech-Unternehmen in der klinischen Entwicklungsphase, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen im Mai und Juni 2025 angekündigt. CEO Sanjay S. Shukla wird auf der RBC Capital Markets Global Healthcare Conference (21. Mai), dem Piper Sandler Virtual Lung Symposium (27. Mai) und der Jefferies Global Healthcare Conference (5. Juni) präsentieren. Die Präsentationen bei RBC und Jefferies werden für 90 Tage als Webcast auf der Firmenwebsite verfügbar sein, und persönliche Treffen mit Investoren sind bei diesen Veranstaltungen möglich. aTyr konzentriert sich auf die Entwicklung bahnbrechender Medikamente basierend auf der Biologie der tRNA-Synthetase, wobei der führende Kandidat efzofitimod auf die Behandlung von interstitiellen Lungenerkrankungen abzielt.
Positive
None.
Negative
None.
SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2025.
Details of the conferences appear below:
Conference: RBC Capital Markets Global Healthcare Conference Date: Wednesday, May 21, 2025 Time: 11:00am EDT Location: New York, NY Format: Fireside Chat
Conference: Jefferies Global Healthcare Conference Date: Thursday, June 5, 2025 Time: 2:00pm EDT Location: New York, NY Format: Fireside Chat
In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the RBC and Jefferies conferences. A webcast of the RBC and Jefferies events will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the events, a replay of the RBC and Jefferies presentations will be available on the aTyr website for at least 90 days. For more information, contact investorrelations@atyrpharma.com.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
What investor conferences will ATYR present at in May-June 2025?
ATYR will present at three conferences: RBC Capital Markets Global Healthcare Conference (May 21), Piper Sandler Virtual Lung Symposium (May 27), and Jefferies Global Healthcare Conference (June 5).
Who will be presenting at the conferences for ATYR?
Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr Pharma, will be presenting at the conferences.
What is ATYR's lead therapeutic candidate?
aTyr's lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator for treating interstitial lung disease.
How can investors access ATYR's conference presentations?
Webcasts of the RBC and Jefferies events will be available on aTyr's website (www.atyrpharma.com) in the Investor's section, with replays available for 90 days after the events.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
